SecBot SecBot

CYTK drug pipeline

CYTOKINETICS INC · 1 rated drug
$56.13
−0.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.6%
1-day, median of 6 events
IV rank
7
IV 51% · HV 52%
Rated drugs
1
1 bullish
Phase 3 trials
2
1 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.

MYQORZO aficamten Updated Nov 13

What to watch

The FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

Bull case
  • MYQORZO is already generating meaningful revenue: $44.5 million in Q3 2026, a 76% sequential increase, with nearly 1,100 U.S. prescribers and over 2,800 patients dispensed.
  • The PDUFA date for the MAPLE-HCM sNDA is November 14, 2026 (tomorrow). MAPLE-HCM showed aficamten was superior to the standard-of-care beta blocker metoprolol, which could strengthen the drug's label and physician adoption.
  • The Phase 3 ACACIA-HCM trial in non-obstructive HCM met both dual primary endpoints. There are currently no approved treatments for nHCM, representing a large untapped market opportunity. A supplemental NDA is expected in Q4 2026.
Bear case
  • Competition from Bristol Myers Squibb's Camzyos (mavacamten), the first-in-class cardiac myosin inhibitor approved for oHCM, could limit MYQORZO's market share and pricing power.
  • The stock trades at roughly half the mean analyst price target of $109.42, suggesting the market is already discounting significant commercial or regulatory risk.
  • Insider selling has been consistent: CEO Robert Blum, EVP Fady Malik, and director B. Lynne Parshall have all sold shares in recent months under 10b5-1 plans, which may signal that internal expectations are tempered.

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Mar 31, 2026MYQORZONDA filed+5.8%+4.5%
Jan 1, 2026MYQORZONDA filed−2.9%−0.3%
Dec 26, 2025MYQORZOPDUFA decision−3.8%−4.5%
Dec 19, 2025MYQORZOApproval+5.5%−0.7%
Dec 1, 2025MYQORZOApproval−6.8%−5.9%
Sep 15, 2025MYQORZONDA filed−2.7%−5.6%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
MYQORZOPhase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCMPhase 3Active not recruiting500Jun 2026
MYQORZOPhase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMPhase 3Completed · results175Feb 28, 2025